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1. Introduction  
The first description of the uterotonic action of pituitary extracts was first described  by Sir 
Henry Dale in 1906 (Dale, 1906). A few years later, Ott and Scott demonstrated that besides 
the effect on uterine activity, posterior pituitary extracts also promoted milk ejection (Ott & 
Scott, 1910). These are the 2 principal activities of oxytocin (OT), the structure and synthesis 
of which were not elucidated until 50 years later by Du Vigneaud and co-workers (Du 
Vigneaud, 1956). OT is mainly produced in the paraventricular nucleus and supraoptic 
nucleus of the hypothalamus, and released from hypothalamic nerve terminals of the 
posterior pituitary, where it is stored, into the bloodstreem. OT differs, by only two amino 
acids, from vasopressin (AVP), which is also produced in these nuclei and stored in the 
posterior pituitary. It was previously believed that OT as well as AVP were exclusively 
released from the neurohypophysis although Ott and Scott (Ott & Scott, 1910) reported that 
the extracts of other tissues such as the  corpus luteum, pineal and thymus glands have the 
same milk-ejecting properties. Early studies associated OT with cardiovascular system  
Paton and Watson first described the blood pressure (BP) depressor response to posterior 
pituitary extract in avians (Paton & Watson, 1912). Hogben & Schlapp confirmed their 
findings and showed the effect of whole posterior pituitary extracts in amphibians and 
reptiles (Hogben & Schlapp, 1924). Furthermore, this effect was evoked by histamine-free 
extracts and was therefore a pituitary action. When separated fractions of posterior pituitary 
extracts obtained by fractional precipitation  became available, Gaddum  showed that the 
depressor response was attributable to the only one fraction, called oxytocin, which had  
oxytocic properties (Gaddum, 1928). These observations were completely overlooked. 
However, recent studies have shown that OT is an ubiquitous hormone, synthesized at 
many locis, and a wide array of physiological activities has been  attributed to this peptide. 
Similar numbers of oxytocinergic neurons have been found in the male and female 
hypothalamus, and the same stimuli induce OT release in both genders, suggesting other 
physiological functions that its role in female reproduction. In fact, OT receptors (OTR) are 
also widely expressed in diverse tissues such as the pituitary, kidney, ovary, testis, thymus, 
heart, vascular endothelium, osteoclasts, myoblasts, pancreatic islets, adipocytes and several 
types of cancer cells (Gimpl & Fahrenholz, 2001). OT elicits a variety of physiological 
responses such as complex sexual and maternal behavior. Indeed, OT is also involved in 
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cognition, tolerance and cardiovascular regulation. OT acts on one type of OTR, an integral 
membrane protein that is a member of the rhodopsin-type (class I) G protein-coupled 
receptor family, which includes AVP receptor subtypes (V1aR, V1bR and V2).  
 
 
Fig. 1. Several oxytocin binding sites are present on oxytocin receptor. This figure illustrates 
molecular docking of the three-dimensional models of activated human oxytocin receptor 
with oxytocin obtained by MolDock Optimizer algorithm from Molegro Virtual Docker 
software. (A) The front upright view position (side view) of the receptor structure with 
oxytocin. (B)   Panel B shows an intracellular view (i.e. rotation by 90º out of plane). (C) 
Conformational view of oxytocin molecule. (D) The schematic model of the human oxytocin 
receptor with marked amino-acid residues that are putatively involved in ligand-binding 
All of these receptors have the ability to bind AVP and/or OT with different affinities. 
Because OT system activation was observed in fetal and newborn hearts at a stage of intense 
cardiac hyperplasia (Jankowski et al., 2004), we hypothesized a role for OT in cardiomyocyte 
(CM) differentiation. The initial experiments demonstrated that OT induces CM 
differentiation of the mouse embryonal carcinoma (EC) P19 cell line, a common stem cell 
model for studying early heart differentiation (Paquin et al., 2002). Then, several studies 
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attempted to understand the mechanisms of cardiac differentiation by OT. Stimulation of 
CM differentiation can be concomitant with neovascularization because OT stimulates 
endothelial cells growth and angiogenesis. In pathological conditions such as cardiac 
ischemia and diabetes this inducer can be used to stimulate production of lost cardiac cells. 
The advantage of this therapy is supported by the fact that OT is endogenously produced in 
the organism, and does not have significant side effects when used in clinics. Moreover, it is 
now possible to inject (transplant) one's own stem cells after previous stimulation with OT 
inducers, as in the case of a heart infarct. Alternatively, direct treatment with OT molecules 
could promote cardiomyogenesis in situ and regeneration of a damaged heart.  
2. OT induces stem cell differentiation 
The manipulations of OT, during the perinatal period have become an accepted—but 
largely unstudied—aspect of human development. For example, synthetic OT  is used to 
induce childbirth (Dudley, 1997). In cases of premature delivery, the OT antagonist (OTA) is 
used for slowing or preventing labor (Husslein, 2002). Although such complex 
manipulations are routine in modern obstetrics, little is known on the possible cellular and 
developmental consequences of these treatments. Several studies have proposed a role for 
OT as a growth and differentiation/maturation factor in a gestational/perinatal context. In 
the mother, OT is required for postpartum alveolar proliferation, and it induces 
differentiation and proliferation of myoepithelial cells in  the mammary gland necessary for 
milk ejection (Gimpl & Fahrenholz, 2001). The OT/OTR system is expressed in human 
cumulus/luteal cells surrounding oocytes, and weak OTR gene expression is even observed 
in oocytes (Furuya et al., 1995). Moreover, when fertilized mouse oocytes are cultured with 
OT in vitro, they develop into the blastocyst stage at a higher rate than their unstimulated 
counterparts (Furuya, et al., 1995).  
On the other hand, hormonal treatment may, in its simplest form, induce mammalian stem 
cells into a special cell type that retains the ability to self-renew (i.e. undergo cell division in 
an undifferentiated state) indefinitely and to differentiate into specialized cells. In this 
regard, it has been suggested that OT plays a role in bone homeostasis and osteoporosis 
based on the proliferative effects of OT on osteoblasts in vitro and the modulation of blood 
parameters associated with bone formation in normal rats (Petersson et al.,  2002b).  
Recently, OT has been  implicated in the regulation of the osteoblast/adipocyte balance of 
human multipotent adipose-derived stem cells and human bone marrow mesenchymal 
stromal cells (Elabd et al., 2008).  
Our interest in the cardiac OT system emerged from long time investigations into the role of 
the brain in the control of cardio-renal homeostasis (Gutkowska & Jankowski, 2008; 
Gutkowska et al., 2000; McCann et al.,  2002). These experiments led to the observations that 
OT and its receptor (OTR) are synthesized in the human and rat heart (Gutkowska et al., 
1997; Jankowski et al., 1998) and that OT exerts cardio-protection either directly or via 
stimulation of mediators such as the natriuretic peptides (NPs) (Gutkowska et al., 1997; 
Gutkowska et al., 2000) and nitric oxide (NO) (Danalache et al., 2007).  Since the study 
showing that OT induces differentiation of EC P19 cells into the functional cardiac muscle 
(Paquin et al., 2002),  several reports have confirmed OT-stimulated cardiomyogenesis in 
different lines of embryonic stem cells (Fathi et al., 2009; Gassanov et al., 2008a; Hatami et 
al.,  2007; Jankowski et al., 2004; Stefanidis et al., 2009; Uchida et al., 2007). In fact, OT can be 
considered as an established myogenic morphogen (Breton et al., 2002).  It  induces 
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differentiation of myoepithelial cells in the mammary gland (Sapino et al., 1993). The 
skeletal myocytes generation has also been observed in OT-induced cardiomyogenesis 
(Danalache et al., 2007) as well as adipogenesis (Bouchard & Paquin, 2009). OT increases the 
rate of myoblast fusion and myotubule formation (Breton et al., 2001). Interestingly, most 
transcription factors identified so far in the heart are also present in other muscle cells, and 
myoblast transplantation to the injured heart improves regional systolic heart function 
(Thompson et al., 2003). Assuming similarities in the differentiation mechanisms of skeletal 
and cardiac muscles and the expression of both OT and OTR in these cells (Breton et al., 
2001; Jankowski  et al., 1998), we can speculate that OT plays a role in cardiac muscle 
regeneration. 
3. OT stimulates CM differentiation in 3-dimensional cultures of stem cells  
EC P19 cells are derived from a teratocarcinoma in CH3/He mice and can differentiate into 
all 3 germ layers (van der Heyden & Defize, 2003).  Developmentally, pluripotent EC P19 
cells appear to differentiate by the same mechanisms as normal embryonic stem cells 
(McBurney, 1993). Culture and differentiation of the cells is simple and cells remain 
undifferentiated without the help of feeder cells or inhibitory factors, and unlike embryonic 
ES cells, they do not spontaneously generate cardiomyocytes. The efficient differentiation of 
EC P19 cells depends on the prior formation of non-adhering cell aggregates (van der 
Heyden & Defize, 2003). Traditionally, cell aggregates formation in suspension culture 
under 0.5–1.0% dimethyl sulfoxide (DMSO) has been used to induce cardiomyocyte 
differentiation of EC P19 cells (McBurney, 1993). Efficiency of cardiac differentiation of ES 
and EC P19 cells in vitro is still not optimal in response to various agents, with yields 
varying between 5% and 20% of cardiomyocytes (Danalache et al., 2007; Gassanov et al., 
2008a; Gassanov et al., 2008b; Gassanov et al., 2007; Paquin et al., 2002). In the EC P19 
model, the order of cardiomyogenesis efficiency was OT (10−7 M) ≥ DMSO >retinoic acid 
(10−8–10−7 M) when these agents were added to cultures during the entire period of cell 
aggregation (Danalache  et al., 2007; Jankowski  et al., 2004; Paquin  et al., 2002). It is 
noteworthy that exposure of EC P19 cells to higher retinoic acid concentration (10−6 M) over 
the aggregation period generates neurons but not muscle cells. 
The presence of OT significantly influences the shape and size of aggregated stem cells 
isolated from the rat heart (Gutkowska & Jankowski, 2009). This suggests that conditions 
inside aggregates, such as hypoxia, promote OTR and OT expression. Indeed, hypoxia can 
influence the functionality of OTR in cardiac cells and mechanism of natriuretic peptides 
secretion in response to OT treatments (Hopkins et al., 2004). Our data indicate that OT 
increases glucose uptake by CMs exposed to chemical hypoxia (Florian et al., 2010).  Multi-
cellular complex aggregate formation and exposure to various agents promotes generation 
of mesodermal or ectodermal lineages. In embryonic D3 stem cells, spontaneously 
producing beating cell colonies upon aggregation, the mesodermal derivatives formed in 
embryoid bodies (EB) include subtypes of cardiac cells (atrial CMs, ventricular CMs and 
pacemaker cells) which are potently enhanced by treatment with OT as identified by 
histological, molecular, and electrophysiological criteria (Gassanov  et al., 2008a). However, 
molecular events occurring during aggregation and the necessity of their aggregation for 
differentiation are not entirely understood. High cell densities can at least trigger 
spontaneous differentiation from EC P19 cells (McBurney, 1993). Skerjanc et al. have 
reported that overexpression of Nkx2.5 can induce cardiomyogenesis in aggregated EC P19 
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cells, but not when they are maintained in monolayer cultures (Skerjanc  et al.,  1998). On the 
other hand, the addition of soluble bone morphogenic protein 4 (BMP 4) into the culture 
media resulted in the requirement for cell aggregation and induced cardiac differentiation 
being bypassed in monolayer cultures of EC P19 cells overexpressing Nkx2.5 (Jamali  et al., 
2001). This result demonstrated that cell aggregation is crucial for the generation of the BMP 
4 signal in EC P19  cells. EC P19Cl6 cells derived from EC P19 cells seem not to be 
committed to a mesodermal lineage but rather represent a stage closer to differentiated 
cardiac muscle than the parental cell line. It was recently observed that OT does not induce 
cardiomyogenesis in monolayers of EC P19Cl6 cells, but does so in aggregates (Uchida et al., 
2007). The same authors suggested that OT-induced cardiac differentiation is not mediated 
by the expression of BMP 4 signaling molecules because the induction of BMP 4 signaling 
cascade can bypass the requirement for prior EB formation (Fathi et al., 2009). 
4. OT molecular forms of OT stimulating differentiation 
OT, recognized as a female reproductive hormone, is largely produced in hypothalamic 
magnocellular neurons of paraventricular and supraoptic nuclei. Biochemical and 
recombinant DNA studies have demonstrated that it is synthesized as a non-glycosylated 
protein, which undergoes an initial endoproteolytic cleavage by the convertase magnolysin 
(EC 3.4.24.62) to OT-Gly-Lys-Arg (OT-GKR) (Brownstein et al.,  1980; Burbach et al.,  2001). 
Subsequent processing produces other OT extended molecules: OT-Gly-Lys (OT-GK) and 
OT-Gly (OT-G) (Burbach et al., 2001), all these forms are often  referred to as OT-X (Morris et 
al., 1992). OT-G is converted by an ǂ-amidating enzyme to C-amidated nonapeptide. OT is 
released into the bloodstream  in this form. OT-X forms have been detected in the 
developing brain of animals and in fetal plasma. In rats, enzymatic OT-X conversion to OT 
is almost complete in adulthood, but not in fetuses, which accumulate OT-X in the brain 
(Altstein et al., 1988a; Altstein & Gainer, 1988b. Similarly, the plasma OT-X elevation 
reported during early fetal development in sheep (Morris et al., 1992)  is reduced in late 
gestation, when OT begins to predominate in the cbloodstream.   
We have recently shown that the OT-GKR is the main form in the fetal heart. This attracted 
our attention because estrogen-mediated BP reduction in humans is associated with 
elevated plasma OT-GKR but not OT, indicating greater bioactivity and stability of this form 
(Light et al., 2005). We have also found that OT-GKR even more potently than OT mediates 
cardiomyogenesis in EC P19 cells (Jankowski et al., 2004) and D3 stem cells (Gassanov et al., 
2008a). The patch-clamp analysis indicates that OT-GKR differentiates D3 cells into CMs of 
the ventricular phenotype and reduces formation of pacemaker cells (Gassanov et al., 
2008a). Furthermore, OT-GKR significantly increases glucose uptake in CM exposed to 
hypoxia (Florian  et al., 2010).  
To determine whether the genetic modification of stem cells also stimulates 
cardiomyogenesis, the OT-Gly-Lys-Arg gene was inserted into D3 stem cells. In effect, we 
observed stimulation of spontaneously-beating embryoid bodies and predominant 
stimulation of cells expressing the ventricular electrophenotype and molecular CM markers 
(Gassanov et al., 2008a). Interestingly, the elongated form of OT, OT-Gly-Lys-Arg, was the 
most potent cardiomyogen of all the OT-like molecules investigated. These findings provide 
a new strategy for the regeneration of diseased hearts. Transgenic cells producing OT-Gly-
Lys-Arg can be injected, for cardioprotection, into the myocardial infarcted rat model. 
Analysis of cardiac remodeling, scar reduction, hemodynamic and echographic parameters 
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together with histochemical and molecular analyses will provide answers as to whether 
these treatments can stimulate cardioprotection. 
5. Mechanism in OT-induced stem cell differentiation 
Some preliminary observations point to a mechanism involved in this process. Ca+2 
mobilization in response to OT treatment has been detected in D3 ES cells differentiating 
into CMs (Gassanov et al., 2008a). It has also been shown that OT-induced differentiation of 
EC P19 stem cells into CMs is inhibited by the NOS inhibitor N(G)-nitro-L-arginine methyl 
ester (L-NAME). 
 
 
Fig. 2. Signal transduction cascades involved in oxytocin-mediated cardiac differentiation of 
P19 embryonal carcinoma cells. See text for details. Akt indicates protein kinase B; ERK, 
extracellular signal-regulated kinase; eNOS, endothelial nitric oxide synthase; midori, 
(myocyte induction/differentiator originator); NP, natriuretic peptides; PI3K, 
phosphatidylinositol 3-kinase; PLC, phospolipase C;  PKC, phosphokinase C, RA, retinoic 
acid 
The NO donor S-nitroso-N-acetylpenicillamine (SNAP) was able to reverse L-NAME-
mediated inhibition of EC P19 cell differentiation into CMs (Danalache  et al., 2007). This 
study clearly indicates a role for NO and NOS enzymes in stem cell differentiation, but it is 
evident that thjis may be a complex process. This complexity is highlighted by the fact that 
suppression of NOS activity by L-NAME has also been shown to increase the number of 
stem and progenitor cells differentiating into CMs (Danalache et al., 2007). Another study 
has reported that exposure of D3 stem cells to AVP increases the number of beating 
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embryoid bodies and also heightens GATA-4 expression. These AVP effects on the cells 
were also found to be antagonized by L-NAME (Gassanov et al., 2007), again suggesting a 
positive role for NO in stem cell differentiation into CMs. This investigation highlighted the 
expression of AVP receptors in undifferentiated D3 cells, with the expression profile 
changing during the differentiation process (Gassanov et al., 2007). It has been observed in 
the EC P19 cell model that AVP not only increases spontaneously-occurring 
cardiomyogenesis but also initiates the process (Gassanov  et al., 2007; Gutkowska  et al., 
2007). 
The OTR-NO-cGMP pathway that is essential for OT-elicited differentiation of EC P19 stem 
cells into CMs is associated with elevation of GATA-4 and myocyte enhancer factor 2c 
(MEF2c) (Danalache  et al., 2007). GATA-4 regulates the expression of genes that are critical 
for CM differentiation. MEF2c is a member of the MEF2 family that is involved in cardiac, 
skeletal, and smooth muscle development. Partial GATA-4 gene targeting in cardiac and 
non-cardiac cells indicates that even modest variations in GATA-4 gene level or activity can 
play a role in the maintenance of normal cardiac function (Bisping et al., 2006). GATA-4 has 
also been implicated in intercellular cross-talk by inducing hypertrophy-associated 
angiogenesis via vascular endothelial growth factor (VEGF) release and targeting the 
endothelium (Heineke et al., 2007). The upstream sequence of OTR contains putative 
binding sites for GATA-4 and Nkx2.5  and GATA-4 also serves as a key transcriptional 
regulator of numerous cardiac peptides, including ANP, BNP and OTR (Uchida  et al., 
2007). GATA-4 has  also been  identified in stem and progenitor cells of the heart in 
combination with OT-mediated CM differentiation (Matsuura et al., 2004; Oyama et al., 
2007). A recent study has demonstrated that undifferentiated murine ES cells express BNP 
and its receptors, with its signaling being essential for cell survival and clonal growth 
(Abdelalim & Tooyama, 2009). This observation suggests possible interaction of the OT and 
NP systems in ES cells during cardiomyogenesis.  
6. Differentiation of endogenous stem cells isolated from animal hearts 
The idea that OT has cardio-regenerative capacities is supported by the observation that this 
hormone induces the differentiation of cultured mice (Matsuura et al., 2004) and rats 
(Oyama et al., 2007) resident cardiac stem cells (CSCs). In the adult heart, CSCs maintain a 
balance of survival, proliferation and self-renewal to replace mature cells that are lost 
during injury or turnover. Matsuura's group revealed the presence of a Sca-1+ stem cell 
population in adult mouse hearts expressing telomerase reverse transcriptase, which has 
been associated with self-renewal potential (Matsuura et al., 2004). These cells, lacking 
hematopoietic markers, are easily distinguished from hematopoietic stem cells of bone 
marrow origin, and when treated with OT, differentiate into functional CMs. Although the 
cells present the early cardiac markers GATA-4 and MEF2, they do not express Nkx-2.5 or 
genes encoding cardiac sarcomeric proteins. When exposed to OT, a small population of 
Sca-1+ cells manifest sarcomeric structures and form spontaneously-beating CMs. In 
addition, after intravenous delivery, Sca-1+ cardiac stem cells can be recruited to the 
myocardium injured by ischemia/reperfusion and can functionally differentiate in situ 
(Matsuura  et al., 2004). Importantly, these cells had positive ionotropic responses to 
isoproterenol via ǃ1-adrenergic receptor signaling. Given the apparently small number of 
CMs generated in vitro by OT stimulation, this raises the questionof whether or not OT-
mediated cardiomyogenesis is a default pathway for CSCs. Accordingly, Matsuura et al.  
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reported that OT induces about 0.5-1% of Sca-1POS ckitNEG CD45NEG cells from the adult 
murine heart to differentiate into functional, spontaneously-beating immature CMs 
(Matsuura, et al., 2004). In this regard, the cardiac differentiation of Sca-1+ cells does not 
require cell aggregation for the process to proceed (Matsuura, et al., 2004). On the other 
hand, a study by the same group in another (CSC) type isolated from the rat heart (Oyama, 
et al., 2007) disclosed that OT treatment resulted in the generation of 5% CMs. These cells, 
termed cardiac side population cells (CSPs), but not to corresponding side population cells 
isolated from bone marrow, differentiated into CMs in response to OT treatment. Therefore, 
OT possesses more powerful cardiogenic activity against CSCs than previously reported. 
CSPs have the ability to efflux Hoechst dye, a process dependent on ABC transporters. 
CSCs, especially Abcg2-dependent CSPs, have been associated with stem/progenitor cells. 
These cells are positive for Abcg2, Sca-1, ckit (low), CD34 (low), CD45 (low) and negative for 
CD31 (Mouquet et al., 2005; Pfister et al., 2005). A possible role for CSCs in heart healing is 
indicated by increased numbers of Abcg2-expressing cells in the border zone adjacent to 
myocardial infarcts (Pfister, et al., 2005). Stimulation of CM differentiation could be 
concomitant with neovascularization because OT stimulates endothelial cell growth 
(Thibonnier et al., 1999)  and angiogenesis (Cattaneo et al.,  2008).  
7. OT mediates cardioprotection 
The absence of either OT or its receptors in knockout mice, however, has not been reported 
to produce cardiac insufficiencies (Nishimori et al., 2008; Takayanagi et al., 2008). Although 
OT knockout mice have a normal heart structure, experiments have shown augmented 
intrinsic heart rates in these animals, indicating that an intracardiac OT system controls 
cardiac electrical activity (Bernatova et al., 2003).  
Although the pathophysiological role of OT is beginning to be understood, accumulating 
evidence indicates multiple beneficial effects in the heart and vasculature. To date, OT’s 
cardiovascular properties include: i. natriuresis (Soares et al., 1999) and decreased blood 
pressure (BP), possibly secondary to atrial natriuretic peptide (ANP) release (Gutkowska  et 
al., 1997; Petersson, 2002a)  ii. negative inotropic and chronotropic effects (Favaretto et al., 
1997; Ondrejcakova et al., 2009) and parasympathetic neuromodulation (Mukaddam-Daher 
et al., 2001); iii. vasodilatation via the OTR-induced NO pathway; iv. endothelial cell growth 
and possible vessel generation (Cattaneo et al., 2008; Cattaneo et al., 2009; Thibonnier  et al., 
1999); and v. modulation of insulin release (Sirotkin et al., 2003) and anti-diabetic actions 
(Florian, et al., 2010). At the cellular level, protective OT: i. has antioxidant properties (Iseri 
et al., 2005a, 2005b) ii. has anti-inflammatory actions (Jankowski et al., 2010a; Szeto et al., 
2008), iii. potentiates glucose uptake in neonatal and adult CMs exposed to hypoxia and 
conditions of insulin resistance mimicked by the presence of ketone bodies (Florian, et al., 
2010) iv. stimulates endothelial markers in mesenchymal cells (Kim et al., 2010)  and stem 
cells isolated from the heart as a side population (Oyama  et al., 2007).  
Central, intraventricular infusion of OT is accompanied by an increase in blood pressure; 
this effect is probably associated with the stimulation of substance P forebrain receptors by 
OT (McCann  et al., 2002). OT’s ability to raise blood pressure is caused not only by its 
vasoconstrictory activity but also by antidiuretic activity. Peripheral administration of OT, 
on the contrary, lowers the average arterial pressure in rats and does not affect heart rate 
(Petersson, 2002a). On the other hand, in the absence of a central regulatory influence, OT 
can bring down the heart rate and reduce the strength of contractions of isolated atria 
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during perfusion of rat hearts (Favaretto  et al., 1997; Mukaddam-Daher et al., 2001). In 
addition, intracardiac OT stimulating the release of ANP may control cardiovascular 
homeostasis and the body’s internal environment (Favaretto  et al., 1997; Gutkowska  et al., 
1997).  
OT’s negative chronotropic action was recently associated with attenuation of cardiac 
damage evinced by ischemia-reperfusion (Ondrejcakova  et al., 2009). Positive cardiac effects 
can also be attributed to the fact that OT stimulates ANP release (Gutkowska  et al., 1997) by 
improving hydromineral homeostasis as well as cardiac hypertrophy and reducing pro-
inflammatory mediators (Jankowski et al., 2010a). ANP, a member of the NPs family that 
includes BNP, C type natriuretic peptide and urodilatin, is released into the circulation after 
volume expansion, atrial stretch (Dietz, 2005), hypoxia (Toth et al., 1994) and in response to 
various hormones and neurotransmitters (Antunes-Rodrigues et al., 1997; McCann et al., 
2002). ANP causes BP to decline with a concomitant increment of diuresis, natriuresis and 
decrease plasma volume (Christensen, 1993; Ruskoaho, 1992). NPs also inhibit the 
sympathetic nervous system and hormones involved in cardiac hypertrophy, such as 
angiotensin II, endothelin and AVP (Gerstberger et al., 1992; Jankowski, 2009; Kaneko et al., 
1988; Mukaddam-Daher et al., 2009; Neuser et al., 993). NPs signaling via functional 
receptors (NPR-A and NPR-B) prevents pathological hypertrophy (Oliver et al., 1997) and 
cardiac fibrosis (Calderone et al., 1998) by attenuating both DNA and collagen synthesis in 
cardiac fibroblasts,  oxidative stress (Baldini et al., 2005; De Vito et al., 2003) and 
inflammation (Kiemer & Vollmar, 2001). Recent reports indicate that BNP and ANP activity 
is associated with lipolysis and postprandial lipid oxidation (Birkenfeld et al., 2008). Both 
hormones modulate fatty acid trafficking and prevent triglyceride accumulation in CMs via 
cGMP signaling (Khairallah et al., 2008).  
The different cardioprotective actions of OT were recently demonstrated in animal models 
of myocardial infarction (MI). In rat and rabbit models of ischemic heart disease, OT 
treatment significantly reduced infarct size and improved parameters of heart function 
(Alizadeh et al., 2010; Houshmand et al., 2009; Jankowski  et al., 2010a; Kim et al., 2010; 
Kobayashi et al., 2009; Ondrejcakova  et al., 2009). 
8. OT Signaling in cardiovascular system 
In cardiac cells, several signaling pathways have also been postulated in conjunction with 
specific functions in the heart. Figure 1 illustrates the hypothetical pathways in the heart 
that are associated with OT-mediated cardioprotection, such as the prevention of apoptosis, 
CM hypertrophy and fibrosis, with stimulation of glucose uptake, cell proliferation and 
differentiation. 
OT signaling depends on coupling to specific G-proteins, cell type and localization on the 
cell membrane surface. As a result, OTR stimulates different second messengers, which 
consequently exerts various physiological effects (Reversi et al., 2005). Due to its organ- and 
tissue-specific expression patterns, it is believed that OTR is regulated largely at the gene 
transcription level (Devost et al., 2008; Zingg & Laporte, 2003). In the cardiovascular system, 
OTR is associated with the ANP-cGMP and NO-cGMP pathways, which reduce the force 
and rate of contraction and increase vasodilatation.  
Our recent report shows that OT increases glucose uptake in CMs via phosphoinositide-3-
kinase (PI3K) and potentiates the glucose uptake effect of 2,4-dinitrophenol, an uncoupler of 
oxidative phosphorylation targeting the mitochondria (Florian, et al., 2010). PI3K pathways 
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are considered beneficial during myocardial injuries (Cantley, 2002; Fujio et al., 2000; Miki et 
al., 2007). The calcium-calmodulin kinase kinase (Ca-CAMKK) and AMP-activated protein 
kinase (AMPK) pathways are also involved in OT-mediated glucose uptake in CMs (Florian 
et al., 2010). AMPK activation in the heart after ischemia and reperfusion is recognized as 
cardioprotective because AMPK limits both apoptosis and cell damage because both limits 
apoptosis and cell damage (Lee et al., 2008; Miki  et al., 2007; Russell et al., 2004). We should 
also consider p38 MAPK and extracellular signal-regulated kinase 1/2 (ERK 1/2) 
phosphorylation which may contribute to OT’s proliferative activity (Devost et al., 2008). 
More recently, in a rabbit model of myocardial ischemia-reperfusion, OT treatment induced 
ERK1/2, AKT and eNOS phosphorylation in cardiac tissues (Kobayashi et al., 2009). 
Therefore, OT, like other G-protein-coupled ligands, can act by PI3K/AKT activation and 
projection onto downstream kinases. Recent studies have demonstrated  that the 
cardioprotective effects of OT are mediated through opening the mitochondrial ATP-
dependent potassium (mitoKATP) channels in the rat heart (Alizadeh  et al., 2010). 
 
 
Fig. 3. Schematic diagram of potential protective pathways of oxytocin in the 
cardiomyocytes. AMPK, AMP activated protein kinase; ANP, atrial natriuretic peptide; 
CaMKK – Ca+2 calmodulin-dependent protein kinase;  AVPR2 –Vasopressin receptor R2; EC, 
endothelial cells; eEF2, eukaryotic translation elongation factor 2; MEK, protein kinase, 
mitogen activated kinase; NFAT, nuclear factor of activated T-cells 
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OT promotes the migration of human dermal EC, breast-derived EC (Cassoni et al., 2006) 
and human umbilical vein EC (HUVEC) (Cattaneo  et al., 2008;  Cattaneo  et al., 2009). The 
pro-migratory effect of OT requires OTR activation of the phosphatidylinositol-3-kinase 
(PI3K)/AKT/eNOS pathway (Cattaneo et al., 2009). Moreover, OT increases proliferation of 
EC and alters gene expression for adhesion molecules and matrix metalloproteinases 
(MMPs), contributing to improved cell motility and growth (Cassoni et al., 2006). 
Angiogenic and anti-apoptotic OT effect was indicated by increased CD31+ microvessels 
(Jankowski et al., 2010b). In this way, OT can control blood flow to the heart. 
9. OT in stem cells therapy  
Cardiovascular disease is one of the leading causes of death throughout the world (Jain et 
al., 2005). Following myocardial infarct (MI), endogenous repair mechanisms are insufficient 
for meaningful regeneration, therefore, muscle lost is replaced by non-contractile fibrotic 
scar (Laflamme et al., 2007). Because cardiomyocytes are unable to regenerate in the adult 
heart, cell-based therapy of transplantation provides a potential alternative approach to 
replace damaged myocardial tissue and restore cardiac function. A major roadblock toward 
this goal is the lack of donor cells, therefore, it is urgent to identify the cardiovascular cells 
that are necessary for achieving cardiac muscle regeneration (Dowell et al., 2003), to treat 
heart failure (Dowell et al., 2003; Raeburn et al., 2002) and restore function. (Hassink et al., 
2003; Orlic et al., 2002).  Several candidates have been investigated: fetal (Li et al., 1997) and 
neonatal (Watanabe et al., 1998) CM, embryonic stem cells (Min et al., 2002; Min et al., 2003),  
cardiac resident stem cells, and skeletal myoblasts (Dimmeler, Zeiher, & Schneider, 2005; 
Leor et al., 1996; Menasche et al., 2001; Menasche et al., 2003; Murry et al., 1996; Taylor et al., 
1998). Alternative source are the bone marrow-derived stem cells (Dimmeler, et al., 2005). 
However, recent studies have questioned the ability of implanted, untreated stem cells to 
generate new CMs (Laflamme et al., 2007; Murry et al., 2004; Noiseux et al., 2006). Most cells 
die within hours of transplantation due to the interplay of ischemia, inflammation, and 
apoptosis (Menasche, 2009; Rosenzweig, 2006).  
Among the cells used, the MSCs are more suitable for the cell therapy because of easy 
isolation, high expansion potential giving an unlimited pool of transplantable cells, low 
immunogenicity, amenability to ex vivo genetic modification and multipotency.  It has been 
shown that injection of MSC either, directly into infarcted hearts (Gnecchi & Melo, 2009) by 
intramuscular (Shabbir et al., 2009) or intraperitoneal injections (Takahashi et al., 2006) 
improves myocardial function and repair. Following exposure to hypoxia and serum 
starvation, conditions that mimic MI, MSC are stimulated to secrete several growth factors 
and cytokines (Gnecchi & Melo, 2009). The exact mechanisms underlying MSC therapeutic 
effects require further investigations and challenges remain in optimizing the culture-
expansion conditions, the MSC capacity for growth factor production and conditions to 
direct stem cells differentiation into CMs or endothelial cells. Recent studies have shown 
that direct injection with OT-treated MSCs into the rat heart after ischemia-reperfusion 
injury improves the engraftment rate and results in an enhanced cardio-protective effect via: 
increased  transmigration activity, the upregulation of matrix metalloproteinase-2 mRNA, 
the integration of MSCs into the myocardium as well as the anti-fibrotic and anti-
inflammatory effects (Kim et al., 2010). 
We propose that MSCs and other types of the stem cells should be treated with OT before 
their  engraftment in vivo. Based on our preliminary data, we expect that preconditioning 
www.intechopen.com
 Embryonic Stem Cells: The Hormonal Regulation of Pluripotency and Embryogenesis 
 
548 
with OT will enhance the capacity of these cells to repair infarcted myocardium due to 
reduced cell death after implantation, increased angiogenic potential, and by enhanced 
secretion of paracrine factors. Alternatively, the therapeutical potential of these cells can be 
improved by the introduction of the OT-expressing construct as recently demonstrated 
(Gassanov et al., 2008a).  
10. Summary and conclusions 
Our research lead to the observation that OT and OTR are synthesized in CMs, and we have 
identified OT as a potent, naturally-occurring cardiomyogenic factor, which by OTR up-
regulation promotes the differentiation of embryonic and somatic stem cells residing in the 
heart to mature and functional CMs.  
All these OT actions have physiological relevance, particularly on glucose uptake in CMs, 
since it is reduced in hearts from insulin-resistant diabetic mice, a disturbance that 
culminates in cardiac dysfunction. 
Understanding the mechanisms of cardiac differentiation by OT can provide therapeutic 
approaches to the management of heart diseases. Currently, it is still extremely difficult to 
obtain new cardiac cells in vitro using stem cells isolated from the heart, as the only method 
that has provided satisfactory results is limited to co-culture with mature CMs. OT and 
some OT agonists, such as OT-Gly-Lys-Arg, that do not interfere with other physiological 
processes in the body (for example, without renal and hemodynamic effects), can 
successfully stimulate the differentiation of stem cell residing in the heart. In pathological 
conditions, such as cardiac ischemia and diabetes, this inducer can serve to stimulate the 
production of cardiac cells lost during the development of these pathologies. The advantage 
of such a therapy is supported by the fact that OT is produced endogenously in the 
organism, and does not have significant side effects when administered clinically. Moreover, 
it is now possible to inject (transplant) stem cells after previous stimulation with OT 
inducers, as in the case of heart attacks. Alternatively, direct treatment with OT molecules 
could promote cardiomyogenesis in situ and the regeneration of damaged hearts. 
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